The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this study is to find out if CagriSema can improve markers that show how chronic kidney disease is progressing in people with type 2 diabetes who are living with overweight or obesity. Participants may also be taking other medicines during the study, such as enalapril maleate, dapagliflozin propanediol, or finerenone, which are used to help protect the kidneys and manage related conditions. The study will measure changes in urine protein levels, kidney function, body weight, waist size, blood sugar control, and blood pressure. It will also track any side effects or health problems that occur during treatment.

During the study, participants will receive their assigned treatment for up to 35 weeks. They will attend regular visits where measurements will be taken and blood and urine samples will be collected to check how well the treatment is working and to monitor safety. The study team will look at changes from the start of the study to the end of treatment to understand the effects of each treatment option.

The purpose of the study is to learn how empagliflozin works in the bodies of children and teenagers with chronic kidney disease, to see if it is safe for them, and to find out if it helps their kidney disease. The study will measure how much of the medicine gets into the blood, check for any unwanted effects, and see if the medicine helps improve kidney function. The study will look at changes in protein levels in the urine, which is one way to measure how well the kidneys are working, and changes in how well the kidneys filter waste from the blood.

The study has two parts. In the first part, participants will be randomly assigned to receive either empagliflozin or placebo for 24 weeks, and neither the participants nor the doctors will know which treatment they are receiving. After this period, there will be an open-label extension where all participants will know they are receiving empagliflozin. The total treatment period can last up to 72 weeks. During the study, participants will continue taking their regular medicines for kidney disease, which may include medicines that help protect the kidneys. Regular check-ups will be done to monitor the participants’ health and kidney function throughout the study.

Participants in the study will receive either survodutide or a placebo through a subcutaneous injection, which is a method of delivering medication just under the skin. During the trial, different doses of the study drug may be administered. The course of the study includes regular monitoring of kidney function and various physical measurements over several months to observe changes in the body.

The purpose of the study is to compare the effects of BI 690517 to Spironolactone on kidney function and how blood flows through the kidneys. Researchers will look at Renal Hemodynamics, which refers to how blood moves through the kidney organs, and changes in protein levels in the blood and urine. The study will monitor how these treatments impact Glomerular Filtration Rate, a measurement used to check how well the kidneys filter waste from the blood, over a period of time.

During the study, participants will be observed at different intervals, specifically at 4 weeks and 26 weeks, to track changes in their kidney health and blood flow. Other substances such as Iohexol or Aminohippuric Acid may be used during certain procedures to help measure kidney performance.

Participants in the study may receive different doses of Levothyroxine Sodium or a placebo. During the study, monitoring will involve checking levels of hormones such as TSH, T4, and T3 in the blood to see how the body is responding to the treatment. Other factors being observed include eGFR, which is a measurement used to check how well the kidneys are filtering waste from the blood, as well as changes in body weight and BMI. The study will follow participants over several months to observe these changes and assess their health-related quality of life.

Participants in the study will be assigned to receive either empagliflozin or a placebo. The treatment involves taking a 10 mg film-coated tablet once daily. During the study, various factors such as body weight, blood pressure, and levels of substances like sodium, potassium, and bicarbonate in the blood and urine will be monitored. Additionally, the HbA1C, which is a measure of average blood sugar levels over time, will be tracked throughout the process.

Participants in the study may receive Baxdrostat, which is taken as an oral tablet, either by itself or combined with Dapagliflozin. In some cases, the medication Forxiga is used, which contains the active substance dapagliflozin. Some individuals may also receive a placebo instead of the second medication. This is a double-blind study, meaning that neither the participants nor the researchers know which specific treatment is being administered during the course of the trial.

The study is designed as a randomized, double-blind, placebo-controlled trial with an extension phase. This means that participants will be assigned by chance to receive either the study medication or placebo, and neither the participants nor the doctors will know which treatment is being given during the main part of the study. The study will involve adults between 18 and 45 years of age who have been diagnosed with Alport syndrome. Participants will need to have certain levels of kidney function and protein in their urine to take part. They will also need to be taking certain medications for their kidneys, specifically medicines known as ACE inhibitors or ARBs, which are commonly used to help protect the kidneys.

During the study, measurements will be taken to see how the treatment affects the amount of protein in the urine over time. The main focus will be on measuring the ratio of protein in the urine at specific time points during the treatment period, specifically at 16, 20, and 24 weeks. The study will also monitor participants for any unwanted effects or side effects that may occur during treatment. After the main treatment period, there will be an extension phase where participants may continue to be followed to gather more information about the long-term effects of the medication.

The purpose of this study is to examine how dapagliflozin and SC0062 work together compared to SC0062 alone in reducing the amount of a protein called albumin in the urine. When kidneys are damaged, they may leak albumin into the urine, and measuring this can show how well the kidneys are functioning. The study will also look at changes in body weight, blood pressure, kidney filtering ability, and markers that indicate fluid retention in the body. Additionally, the study will monitor any side effects that occur during treatment with these medications.

This is a crossover study, which means participants will receive different treatment combinations during different periods of the study. Each treatment period will last for 8 weeks. During the study, participants will take either SC0062 alone or a combination of both dapagliflozin and SC0062. Participants will need to continue managing their diabetes with insulin and monitoring their blood sugar levels at home as they normally do. Throughout the study, regular check-ups will be conducted to measure urine albumin levels, kidney function, and overall health to see how the treatments are working.

The study will involve people with chronic kidney disease who are scheduled for heart surgery such as coronary artery bypass grafting (a procedure to improve blood flow to the heart), aortic valve surgery (repair or replacement of the valve between the heart and the main artery), mitral valve surgery (repair or replacement of the valve between the upper and lower chambers on the left side of the heart), or a combination of these procedures. Participants will receive the study medication or placebo before their surgery. After the surgery, they will be carefully monitored in the hospital to check their kidney function by measuring substances in their blood and urine. The medical team will watch for any side effects or complications, particularly during the first 72 hours after surgery.

The observation period will continue for about 90 days after the surgery. During this time, participants will have follow-up visits where doctors will check their kidney function, heart function using ultrasound imaging of the heart called echocardiography, and measure specific markers in the blood such as NT-proBNP, which indicates how well the heart is working. The study will track whether participants develop kidney injury after surgery, how severe it becomes, how long it takes for kidney function to return to normal, and whether any participants need dialysis, which is a treatment that filters the blood when the kidneys cannot do so properly. The medical team will also monitor oxygen levels in the blood and record any adverse events or serious health problems that occur throughout the study period.

The purpose of the study is to find out if finerenone is better than placebo in reducing the amount of protein in the urine over six months. Protein in the urine is a sign that the kidneys are not working properly. The study will also look at the safety of finerenone by checking for side effects and monitoring potassium levels in the blood, as high potassium can be a concern with this type of medication.

Participants in this study will be randomly assigned to receive either finerenone or placebo for a treatment period that can last up to 175 days. During the study, participants will have regular check-ups where doctors will measure the protein levels in their urine and monitor their overall health. The study is designed to be double-blind, which means that neither the participants nor the doctors will know who is receiving finerenone and who is receiving placebo until the study is completed.

The purpose of this research is to evaluate if eplerenone can be safely used in patients who have both heart and kidney conditions, and to determine how well it works. The study will monitor how many patients can complete the treatment while maintaining safe levels of potassium in their blood. Some patients may need to take additional medication called a potassium binder during the study.

During this twelve-month study, participants will receive eplerenone through oral tablets. The medication dose will start at a lower amount and may be adjusted over time. Throughout the study, doctors will monitor various aspects of heart and kidney function, including blood tests and physical assessments. They will also track any changes in symptoms and overall health status.

The study will compare two different approaches to taking these medications. In one approach, participants will start both medications at the same time. In the other approach, participants will start taking one medication first and add the second medication later. Some participants will receive a placebo instead of vicadrostat. The study will last for 14 weeks, during which participants will take their assigned medications daily.

Throughout the study, doctors will monitor how well the kidneys are working by measuring kidney function through blood tests. They will also check blood pressure and other health indicators to ensure the medications are safe and working as intended. This research could help determine the best way to give these medications to people with chronic kidney disease in the future.

The main purpose is to understand how these medications can help protect kidney function and improve blood vessel health in people with CKD. During the study, participants will receive different doses of the medications: semaglutide injections ranging from 0.25 mg to 1 mg, and finerenone tablets in either 10 mg or 20 mg strengths.

The study will measure how well the medications work by looking at changes in the amount of protein in participants’ urine, which is an important indicator of kidney health. The treatment will involve two separate periods: first, participants will receive either semaglutide or no treatment, and then in the second period, all participants will receive finerenone in addition to their existing treatment.

Participants in the study will receive one of the two treatment combinations. The first group will take tacrolimus and MTOR inhibitors, while the second group will take tacrolimus and mycophenolic acid. Both groups will be monitored for their immune response to CMV before the transplant and at 15, 30, and 90 days after the transplant. The study will also track the presence of CMV infection or disease six months after the transplant to evaluate the effectiveness of each treatment approach.

The study will last until the end of 2026, with recruitment starting in mid-2025. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatments. The findings from this study could help improve the management of CMV infection in kidney transplant recipients, potentially leading to better outcomes for patients with advanced chronic kidney disease.

Participants in the study will take Camostat Mesilate in the form of a tablet. The study will monitor various health indicators, including urine sodium and water excretion, body weight, and blood pressure at home. Additionally, the study will look at urine protease activity, which involves enzymes that break down proteins, and other markers in the urine and blood that can provide insights into kidney function and health.

The study will take place over a period of time, with participants being closely monitored to understand the effects of the medication. The goal is to gather information that could help improve treatment options for people with CKD. Participants will be required to maintain their usual antihypertensive treatment, which is medication to manage high blood pressure, throughout the study. The study is expected to conclude by the end of 2025.

The study is divided into two parts. In the first part, researchers aim to develop a tool that helps determine the right dose of Sevuparin for each individual based on their kidney function. This is done by looking at how the body processes the medication. In the second part, the study will look at changes in important blood and kidney health markers after multiple doses of Sevuparin are given to participants with CKD. These markers include things like blood cell levels and kidney function indicators.

Throughout the study, participants will be closely monitored for safety, with regular checks on their heart activity, vital signs, and blood tests. The study will also assess any side effects that may occur. The goal is to gather information that could lead to better treatment options for people living with Chronic Kidney Disease.

The purpose of the study is to understand how these kidney diseases change the way the kidneys process energy. By using the MRI with the special pyruvate injection, researchers hope to see differences in how the kidneys of healthy people and those with kidney disease work. This includes looking at how the kidneys produce certain substances like lactate and alanine, which are related to energy use in the body. The study will include healthy volunteers as well as patients with chronic kidney disease and polycystic kidney disease.

Participants in the study will receive the pyruvate injection and then undergo an MRI scan. This will help researchers see the metabolic changes in the kidneys. The study aims to find out if these changes are linked to other signs of kidney damage, such as fibrosis (scarring) and inflammation, which are often seen in kidney disease. The information gathered from this study could help improve understanding of these diseases and lead to better ways to diagnose and treat them in the future.

Participants in the study will receive either Kerendia or a placebo, taken orally as a tablet. The study will last for a period of up to 24 months. During this time, participants will continue to receive their standard care for CKD. The study aims to observe changes in kidney function, specifically looking at the estimated glomerular filtration rate (eGFR), which is a measure of how well the kidneys are working. The study will also monitor other health outcomes, such as changes in protein levels in the urine and the occurrence of cardiovascular events like heart attacks or strokes.

The trial will help researchers understand if Kerendia can effectively slow down the progression of CKD and improve the quality of life for those affected by this condition. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on the medication’s effects. The findings from this study could lead to better treatment options for people living with CKD.

Participants in the study will be randomly assigned to receive either the combination of Baxdrostat and Dapagliflozin or Dapagliflozin with a placebo. A placebo is a substance with no active medication. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, ensuring unbiased results. The treatment period will last up to 60 days, and participants will take the medication in the form of tablets.

The study aims to monitor the health of the participants over time, focusing on changes in kidney function and heart health. The researchers will look for any significant decline in kidney function, the need for dialysis or kidney transplant, and any heart-related deaths. The study will also track changes in blood pressure and other health markers. This research hopes to provide valuable insights into better treatment options for people with CKD and high blood pressure.

The purpose of the study is to compare the effects of this targeted treatment approach with the standard care currently used for CKD. Participants in the study will receive one of the medications or a placebo. The study will last for about two years, during which time participants will take the medication and have regular check-ups to monitor their kidney function and overall health. The main focus will be on how the treatment affects the rate of change in kidney function over time.

Throughout the study, changes in kidney function will be measured by looking at the estimated glomerular filtration rate (eGFR), which is a test that shows how well the kidneys are working. Other aspects, such as changes in protein levels in the urine and a special score called the KidneyIntelX score, will also be monitored. The study aims to provide valuable information that could lead to better treatment options for people with CKD.

The purpose of the study is to see if finerenone can help reduce a specific measure related to kidney function over a period of six months. Participants in the study will be randomly assigned to receive either finerenone or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study will take place over several months, and participants will continue to receive their standard care for chronic kidney disease and type 1 diabetes while participating in the trial.

Throughout the study, researchers will monitor participants for any changes in their kidney function and any side effects that may occur. The main focus will be on changes in a specific kidney-related measure, and researchers will also keep track of any adverse events, including any significant increases in potassium levels, which is a potential side effect of the treatment. The study is designed to provide valuable information about the potential benefits and safety of finerenone for people with chronic kidney disease and type 1 diabetes.

The purpose of the study is to determine how effective Ketoanalogue supplementation is in preventing muscle loss, a condition known as sarcopenia, over a period of 12 months. Participants will be asked to take the tablets orally and will have their muscle mass and other health indicators monitored at various intervals throughout the study. This includes checking their weight, body mass index (BMI), and levels of certain proteins and minerals in the blood. The study will also assess muscle strength and performance through tests like grip strength and walking speed.

By participating in this study, researchers hope to gather valuable information on how Ketoanalogue supplementation can benefit patients with advanced stages of chronic kidney disease. The ultimate goal is to improve the quality of life for these patients by maintaining their muscle health while they manage their kidney condition with a low protein diet.

The purpose of the study is to evaluate the safety of the Eight Treg treatment when used alongside these standard medications. Participants will receive the Eight Treg infusion the day before their kidney transplant. The study will monitor participants for up to three months after the transplant to check for any side effects or complications. The study will also look at how the treatment affects the immune system and the new kidney over time.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the function of their new kidney. These tests will include blood tests and possibly biopsies of the kidney to ensure everything is working as expected. The study aims to provide valuable information on how well the Eight Treg treatment works in helping kidney transplant patients and how safe it is to use with other medications.

Participants in the study will be randomly assigned to receive either dapagliflozin or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for about six months, during which time the participants will continue their regular hemodialysis treatments while taking the study medication or placebo. The main focus will be on changes in the heart’s structure and function, particularly the Left Ventricular Mass, which is a measure of the heart’s size and health.

Throughout the study, various health markers will be monitored, including blood sugar levels, hormones, and heart function indicators. The goal is to see if dapagliflozin can improve heart health and overall quality of life for patients on hemodialysis. The study will provide valuable information on whether this medication can be beneficial for people with kidney and heart conditions who are undergoing hemodialysis.

The main purpose of this study is to understand how different doses of NNC0519-0130 can help reduce kidney damage. The study will look at how well the treatments work by measuring the amount of protein in the urine, which is an indicator of kidney health. Other aspects being studied include changes in kidney function, body weight, waist size, blood pressure, and blood sugar control.

The study will last for 36 months, during which participants will receive their assigned treatment through an injection pen. Throughout the study, participants will have regular check-ups to monitor their health and any potential side effects. The treatment will be given using a special pre-filled injection pen that delivers the medication under the skin.

Participants in the study will be randomly assigned to receive either the new drug BAY 3283142 or a placebo, in addition to their standard care. The study will last for 16 weeks, during which time the participants will take the medication orally. The researchers will monitor changes in the urine albumin-creatinine ratio, which is a measure used to assess kidney function. This will help determine the most effective dose of the new drug for future studies.

Throughout the study, participants will have regular check-ups to monitor their kidney function and overall health. The study aims to find the best dose of BAY 3283142 to help reduce albumin in the urine, which could potentially improve kidney health in people with chronic kidney disease. The results of this study will help guide further research and development of this treatment.

Participants in the study will be divided into groups. One group will receive Lokelma along with RAAS inhibitors, while the other group will receive RAAS inhibitors without Lokelma. The study will last for about three months, during which the effectiveness of the treatment will be monitored. The goal is to see if patients can safely increase their dose of RAAS inhibitors, which are important for managing heart failure and chronic kidney disease, by at least 25% compared to their initial dose. This will help determine if Lokelma can help patients better tolerate higher doses of RAAS inhibitors.

Throughout the study, various health parameters will be observed, such as changes in blood pressure and kidney function, as well as the number of hospital visits related to heart failure, hyperkalemia, or impaired kidney function. The study aims to provide valuable insights into how Lokelma can be used to improve the management of heart failure and chronic kidney disease in elderly patients, potentially leading to better health outcomes and quality of life.

Participants in the study will be randomly assigned to receive either dapagliflozin or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for 12 weeks, during which time the effects of the treatment on blood vessel function will be monitored. This will involve measuring how well the blood vessels can expand in response to increased blood flow, which is an important aspect of vascular health.

The goal of the study is to determine if dapagliflozin can improve the health of blood vessels in people with chronic kidney disease. This could potentially lead to better management of the disease and improved overall health outcomes for patients. The study will also look at other factors, such as changes in certain substances in the blood that are related to inflammation and blood vessel function, to gain a better understanding of how dapagliflozin might benefit these patients.

The medication being studied, Lokelma, is a type of drug known as a cation exchanger that helps remove excess potassium from the body. Patients will receive either Lokelma powder at doses up to 10 grams per day or continue with their usual care for managing high potassium levels. The treatment period will last for 60 days, during which doctors will monitor the patients’ potassium levels regularly.

During the study, patients will be randomly assigned to one of two treatment groups. One group will receive Lokelma, while the other group will follow standard treatment procedures. The study will track how many patients in each group achieve normal potassium levels over a period of 90 days. Blood tests will be performed throughout the study to measure potassium levels.

Participants in the study will receive either the active medication or a placebo, which looks like the medication but does not contain the active ingredient. The study will observe changes in the heart and kidney health of participants over a period of time. This includes monitoring the heart’s structure and function using a technique called magnetic resonance imaging (MRI), as well as measuring protein levels in urine to assess kidney function.

The trial will also look at other health indicators, such as blood pressure and certain markers in the blood and urine that are related to heart and kidney health. The goal is to determine if the combination of finerenone and SGLT2 inhibitors provides additional benefits in protecting the heart and kidneys compared to current treatments. The study is expected to continue until 2027, providing valuable insights into the management of type 2 diabetes and chronic kidney disease.

Participants in the study will be randomly assigned to receive either the medication or a placebo. The study will observe changes in the kidney’s structure, specifically looking at certain cells and markers that indicate inflammation and stress within the kidney tissue. These observations will be made during a routine biopsy, which is a procedure where a small sample of kidney tissue is taken for examination, one year after the kidney transplant.

The study will last for a period of 12 months, during which the effects of dapagliflozin on the kidney will be closely monitored. The goal is to understand whether this medication can help improve kidney health in patients who have received a kidney transplant and are dealing with Chronic Kidney Disease.

Participants in the study will take either Finerenone or a placebo orally for a period of up to 104 weeks, which is about two years. Throughout the study, the health of the participants will be monitored to see how their kidney function changes over time. The study will also look at other health outcomes, such as changes in protein levels in the urine, the occurrence of kidney failure, and any cardiovascular events like heart attacks or strokes.

The study will also assess the safety and tolerability of the treatment, as well as its impact on the quality of life of the participants. By the end of the study, researchers hope to determine whether Finerenone is an effective treatment option for people with Chronic Kidney Disease and if it can be used to improve their overall health outcomes.

Participants in the study will receive either patiromer or a placebo. The study will last for a period of up to 12 months. During this time, researchers will monitor the participants’ kidney function and blood pressure. The main goal is to see if patiromer can help reduce the amount of protein in the urine, which is a sign of kidney damage, and to see if it allows for an increase in the dose of RAAS-blocker medications.

In addition to monitoring protein levels in the urine, the study will also look at other factors such as blood pressure, potassium levels in the blood, and overall kidney function. The study will help determine if patiromer is a beneficial treatment option for people with CKD who are taking RAAS-blocker medications. The results of this study could provide important information for improving the care of patients with chronic kidney disease.

The purpose of the study is to determine if dapagliflozin is more effective than a placebo in improving kidney and heart health outcomes. Participants in the study will be randomly assigned to receive either the medication or a placebo. The study will include patients with advanced CKD, those on dialysis, and kidney transplant recipients. The trial will monitor the time it takes for participants to experience kidney failure, hospitalization due to heart failure, or death from any cause.

Throughout the study, participants will take the medication or placebo orally, in the form of a film-coated tablet, for a period of up to 48 weeks. The study aims to provide valuable insights into whether dapagliflozin can help improve the health and quality of life for people with severe chronic kidney disease by potentially reducing the risk of kidney failure and heart-related issues.

Participants in the study will follow a potassium-rich diet, and the effects will be monitored over a period of six weeks. The study will compare the changes in blood potassium levels from the beginning to the end of the study. Additionally, the study will observe other health indicators such as blood pressure, kidney function, and quality of life. The study will also look at the effects on bowel movements and the occurrence of severe hyperkalemia, which is a condition where there is too much potassium in the blood.

The trial aims to ensure that the potassium-rich diet, along with the use of sodium zirconium cyclosilicate, is safe for patients with chronic kidney disease. The study will help understand if this approach can be a viable option for managing potassium levels in these patients without causing harm. The trial is expected to start recruiting participants in early 2024 and will continue until early 2025.

Participants in the study will receive either Tacrolimus or mycophenolate mofetil, or a combination of both, as part of their regular treatment after a kidney transplant. The study will observe changes in the gut microbiota and how these changes might influence the effectiveness and processing of the medications. The study will also involve monitoring the participants over a period of time to gather data on how the medications are absorbed and metabolized in the body.

The study aims to provide insights into the variability of how different patients respond to these immunosuppressant drugs, which are crucial for the success of kidney transplants. By understanding these differences, the study hopes to improve treatment plans and outcomes for future patients undergoing kidney transplants. Participants will be monitored closely throughout the study to ensure their safety and to collect necessary data for the research.

Participants in the study will be randomly assigned to receive either the combination of Zibotentan and Dapagliflozin or Dapagliflozin alone. Some participants may receive a placebo. The study will last for about 24 months, during which time participants will take the medication orally, in the form of a film-coated tablet. Throughout the study, participants will have regular check-ups to monitor their kidney function and overall health. The main focus will be on changes in kidney function over time, as well as other health indicators related to kidney disease.

This study aims to provide valuable information on whether the combination of Zibotentan and Dapagliflozin can offer better protection for the kidneys in people with Chronic Kidney Disease and High Proteinuria. By participating, individuals will contribute to research that could lead to improved treatments for this condition in the future.